Axial Biotech Has Developed the First Scoliosis Prognostic Test
Written by Herina Ayot on Feb 13, 2011
Scoliosis is a degenerative spinal cord disease that leads to painful and debilitating spinal curvature, and this condition has a high-need for comprehensive diagnostics. Axial Biotech, a biopharmaceutical company, has developed the first scoliosis prognostic test that not only determines how the disease will progress, but does so in a patient-specific manner, enabling personalized medicine and the development of patient tailored treatment plans by doctors. The test is used in patients diagnosed with Scoliosis, and screens for genetic mutations that indicate how the disease will progress in each individual.
One Response to “Axial Biotech Has Developed the First Scoliosis Prognostic Test”
Leave a Reply
[...] This post was mentioned on Twitter by OneMedPlace, Chelli Miller. Chelli Miller said: Axial Biotech Has Developed the First #Scoliosis Prognostic Test http://goo.gl/fb/amD0B #diagnostics #sentinel2 [...]
These sort of tests are amazing steps forward in properly treating scoliosis patients. Knowing where the disease is and how it will progress allows for customization of treatment programs for each patient.